These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25281978)

  • 1. Validation of simplified dosimetry approaches in ⁸⁹Zr-PET/CT: the use of manual versus semi-automatic delineation methods to estimate organ absorbed doses.
    Makris NE; van Velden FH; Huisman MC; Menke CW; Lammertsma AA; Boellaard R
    Med Phys; 2014 Oct; 41(10):102503. PubMed ID: 25281978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
    Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
    J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An automatic delineation method for bone marrow absorbed dose estimation in (89)Zr PET/CT studies.
    Makris NE; Boellaard R; Menke CW; Lammertsma AA; Huisman MC
    EJNMMI Phys; 2016 Dec; 3(1):13. PubMed ID: 27447823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
    Rizvi SN; Visser OJ; Vosjan MJ; van Lingen A; Hoekstra OS; Zijlstra JM; Huijgens PC; van Dongen GA; Lubberink M
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):512-20. PubMed ID: 22218876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interobserver reproducibility of tumor uptake quantification with
    Jauw YWS; Bensch F; Brouwers AH; Hoekstra OS; Zijlstra JM; Pieplenbosch S; Schröder CP; Zweegman S; van Dongen GAMS; Menke-van der Houven van Oordt CW; de Vries EGE; de Vet HCW; Boellaard R; Huisman MC
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1840-1849. PubMed ID: 31209514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and estimation of radiation-absorbed doses in humans for 13N-ammonia PET.
    Yi C; Yu D; Shi X; He Q; Zhang X; Zhang X
    Ann Nucl Med; 2015 Nov; 29(9):810-5. PubMed ID: 26243501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.
    Jauw YWS; Heijtel DF; Zijlstra JM; Hoekstra OS; de Vet HCW; Vugts DJ; Verheul HM; Boellaard R; Zweegman S; van Dongen GAMS; der Houven van Oordt CWM; Lammertsma AA; Huisman MC
    Mol Imaging Biol; 2018 Dec; 20(6):1025-1034. PubMed ID: 29713958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dosimetry and biodistribution of the translocator protein radiotracer [(11)C]DAA1106 determined with PET/CT in healthy human volunteers.
    Brody AL; Okita K; Shieh J; Liang L; Hubert R; Mamoun M; Farahi J; Mandelkern MA
    Nucl Med Biol; 2014; 41(10):871-5. PubMed ID: 25156039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
    Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A
    Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (S)-4-(3-18F-fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging--dosimetry.
    Smolarz K; Krause BJ; Graner FP; Wagner FM; Hultsch C; Bacher-Stier C; Sparks RB; Ramsay S; Fels LM; Dinkelborg LM; Schwaiger M
    J Nucl Med; 2013 Jun; 54(6):861-6. PubMed ID: 23568366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved accuracy of the biodistribution and internal radiation dosimetry of
    Yu X; Sun H; Xu L; Han Y; Wang C; Li L; Ng YL; Shi F; Qiu J; Huang G; Zhou Y; Chen Y; Liu J
    Med Phys; 2023 Sep; 50(9):5865-5874. PubMed ID: 37177847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET.
    Walrand S; Jamar F; van Elmbt L; Lhommel R; Bekonde EB; Pauwels S
    J Nucl Med; 2010 Dec; 51(12):1969-73. PubMed ID: 21078802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of sequential SPECT and CT for targeted radionuclide therapy dosimetry.
    Li T; Wu NY; Song N; Mok GSP
    Ann Nucl Med; 2018 Jan; 32(1):34-43. PubMed ID: 29143283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phantom validation of coregistration of PET and CT for image-guided radiotherapy.
    Lavely WC; Scarfone C; Cevikalp H; Li R; Byrne DW; Cmelak AJ; Dawant B; Price RR; Hallahan DE; Fitzpatrick JM
    Med Phys; 2004 May; 31(5):1083-92. PubMed ID: 15191296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
    Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
    Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter harmonization of 89Zr PET/CT performance.
    Makris NE; Boellaard R; Visser EP; de Jong JR; Vanderlinden B; Wierts R; van der Veen BJ; Greuter HJ; Vugts DJ; van Dongen GA; Lammertsma AA; Huisman MC
    J Nucl Med; 2014 Feb; 55(2):264-7. PubMed ID: 24357686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation Dosimetry of a Novel Adenosine A
    Zhou X; Elsinga PH; Khanapur S; Dierckx RA; de Vries EF; de Jong JR
    Mol Imaging Biol; 2017 Apr; 19(2):289-297. PubMed ID: 27539309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.